Prothrombotic effect of erythropoietin in dialysis patients

TY - JOUR

T1 - Prothrombotic effect of erythropoietin in dialysis patients

AU - Taylor, J. E.

AU - McLaren, M.

AU - Henderson, I. S.

AU - Belch, J. J. F.

AU - Stewart, W. K.

PY - 1992

Y1 - 1992

N2 - Thrombin-antithrombin III complex concentrations (TAT-III) were measured in 18 anaemic haemodialysis patients treated with erythropoietin (Epo) and in four haemodialysis patients treated with i.v. iron dextran. There was a significant early increase in thrombin-antithrombin III in erythropoietin-treated patients which appeared to be independent of the response to erythropoietin (Epo responders (n= 14), pretreatment TAT-III median (range) 3.10 (2.70-9.10) µg/l; maximum TAT-III 19.48 (11.18-60.00) µg/l, P< 0.001, Wilcoxon; Epo non-responders (n = 4), pretreatment TAT-III 3.15 (2.90-4.50) µg/l, maximum TAT-III 16.00 (10.31-36.12) µg/l, P<0.001). This was not seen in iron-dextran-treated patients (Pretreatment TAT-III 2.05 (1.90-9.48) µg/l, maximum TAT-III 5.60 (2.10 14.50) µg/l). The change was not related to haemoglobin, erythropoietin dose, or method of administration, and was transient in nature, thrombin antithrombin III returning to pretreatment values after approximately 6 months in all patients (Epo responders 6.0(4.0-9.0) months, TAT-III 2.47 (1.30-9.23) µg/l; Epo non-responders 7.0 months, TAT-III 5.04 (2.10-7.00) ug/l). Increased thrombin antithrombin III complex may reflect an effect of erythropoietin on microcirculatory factors, which could be relevant to the occurrence of adverse events during treatment.

AB - Thrombin-antithrombin III complex concentrations (TAT-III) were measured in 18 anaemic haemodialysis patients treated with erythropoietin (Epo) and in four haemodialysis patients treated with i.v. iron dextran. There was a significant early increase in thrombin-antithrombin III in erythropoietin-treated patients which appeared to be independent of the response to erythropoietin (Epo responders (n= 14), pretreatment TAT-III median (range) 3.10 (2.70-9.10) µg/l; maximum TAT-III 19.48 (11.18-60.00) µg/l, P< 0.001, Wilcoxon; Epo non-responders (n = 4), pretreatment TAT-III 3.15 (2.90-4.50) µg/l, maximum TAT-III 16.00 (10.31-36.12) µg/l, P<0.001). This was not seen in iron-dextran-treated patients (Pretreatment TAT-III 2.05 (1.90-9.48) µg/l, maximum TAT-III 5.60 (2.10 14.50) µg/l). The change was not related to haemoglobin, erythropoietin dose, or method of administration, and was transient in nature, thrombin antithrombin III returning to pretreatment values after approximately 6 months in all patients (Epo responders 6.0(4.0-9.0) months, TAT-III 2.47 (1.30-9.23) µg/l; Epo non-responders 7.0 months, TAT-III 5.04 (2.10-7.00) ug/l). Increased thrombin antithrombin III complex may reflect an effect of erythropoietin on microcirculatory factors, which could be relevant to the occurrence of adverse events during treatment.

M3 - Article

C2 - 1314996

SN - 0931-0509

VL - 7

SP - 235

EP - 239

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

IS - 3

ER -